Immune cell infiltration and tumour microenvironment, immune checkpoint inhibitors, immunomodulators, immune cell markers, and therapeutic outcomes in clinical studies of immune checkpoint blockade were subsequently explored, and we identified significant correlations with PROS1 expression. Here, PROS1 is linked to neoplasm.